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Previewswork has important implications for our
understanding of natural resistance to
viral disease and as such may lead to
the development of novel approaches
for coping with viral infections. However,
as in the case of all important new find-
ings, the results from this study set the
stage for many new questions that need
to be addressed. As suggested by the
authors, it is likely that the infection results
in the presentation of novel viral or cellular
peptide(s) by Qa-1b because reporter
cells expressing CD94-NKG2E receptors
were not stimulated unless target
cells were infected. Could it be that
Qa-1b-peptide complexes on ectrome-
lia-infected cells exhibit a higher affinity
for CD94-NKG2E? The effect of Qa-1b
deficiency on the mortality rate is much
lower than in Klrd1/ mice, suggesting
the existence of another molecule
involved in CD94-NKG2 signaling. It is
known that CD94 is also expressed on
NKT, gdT cells, and some activated
CD8+ T cells, so it is important to assess
the contribution of these individual cell
subsets in the described phenotype.
Late kinetics of mortality in mice lacking
CD94 suggests that, in addition to NK460 Immunity 34, April 22, 2011 ª2011 Elsevcells, a compromised CD8+ T cell
response might be an immediate cause
of death of mice.
The most puzzling question is the mode
of synergism between NKG2D and CD94-
NKG2E receptors. Is the engagement
of NKG2D by its natural ligands required
to synergize with CD94-NKG2E or does
NKG2D act by stabilizing the CD94-
NKG2E complex by docking next to it?
Alternatively, does CD94-NKG2E act to
stabilize sustained NKG2D expression?
The expansion of CD94-NKG2C has also
been established during HCMV infection,
suggesting the possibility that the involve-
ment of these activating receptors is not
necessarily specific for a single virus
(Guma et al., 2006). Having in mind that
poxviruses share great homology and
the fact that CD94-NKG2 receptors are
well conserved between rodents and
primates, one could speculate that CD94
function might be driven by poxvirus
evolution. Results obtained with the
mousepox virus model indicate that there
is constant pressure for a novel innate
immune response mechanism to resist
viral immunoevasion and virus-induced
pathology.ier Inc.REFERENCES
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In this issue of Immunity, Chaudhry et al. (2011) and Huber et al. (2011) report that control of Th17 cell
responses during colonic inflammation requires direct signaling by IL-10 in regulatory T cells and Th17 cells.Inflammatory responses due to com-
mensal microorganisms or pathological
stimuli are held in check by a variety of
processes involving suppressive cyto-
kines, other soluble mediators, and sup-
pressive populations of inflammatory
cells. The cytokine interleukin-10 (IL-10)
and regulatory T (Treg) cells, such as
FoxP3+ Treg and FoxP3 Tr1 cells, play
both unique and overlapping roles in this
control. IL-10 has regulatory functions
on both innate and adaptive responsesthat are mediated in part by its effects
on antigen-presenting cells, in which it
reduces secretion of proinflammatory
cytokines such as TNF and IL-12 and
lowers expression of costimulatory mole-
cules (Ma and Trinchieri, 2001; Moore
et al., 2001). IL-10 is produced by several
cell types including Treg cells. Treg cells,
on the other hand, regulate immune
responses through multiple mechanisms
including the production of suppressive
cytokines such as IL-10, TGF-b, andIL-35, but also depletion of energy and
growth factors (e.g., ATP and IL-2),
cytolysis of antigen-presenting cells, and
inhibition of antigen-presenting cell
maturation (Vignali et al., 2008). In vitro
assays of Treg cell activity are poor at
modeling their requirements for IL-10.
However, a clear requirement for Treg
cell IL-10 is seen in vivo where it plays
a key role in regulation of inflammation
at environmental interfaces such as the
intestine and the lung. The studies by
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Figure 1. Treg Cell-Mediated Regulation of Th17 Cell Functions Requires IL-10 Signaling
in Both Cell Types
IL-10 signaling in Treg cells activates STAT3 that is required for the expression of CCR6, IL-1R, IL-6R, the
EBI3 chain of the immunosuppressive cytokine IL-35, and in part, IL-10. CCR6 expressed by STAT3+ Treg
and Th17 cells attracts both cells because its ligands are produced in inflamed tissues and by Th17 cells,
particularly at environmental interfaces. The expression of IL-6R and IL-1R on Treg cells may compete for
the availability of IL-6 and IL-1 that are required for Th17 cell differentiation. In addition, IL-10 produced by
STAT3+Foxp3+ Treg or by Foxp3 Tr1 cells acts directly on Th17 cells to suppress their function but has no
direct effect on Th1 and Th2 lineage cells.
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PreviewsChaudhry et al. (2011) and Huber et al.
(2011) clarify the mechanisms linking
regulatory T cells and IL-10 by demon-
strating that IL-10 directly signals in
Th17 and Treg cells to maintain control
of Th17 cell-mediated inflammation.
Treg cells can co-opt part of the
transcription program of the Th1, Th2,
and Th17 effector T cell lineages they
regulate, thus assisting migration to the
same inflamed tissue and potentially
allowing selective regulation of a specific
T cell lineage. For example, in type I
inflammation, Treg cells exposed to inter-
feron-g upregulate the Th1 cell-specific
transcription factor T-bet. T-bet is
required for the survival and function of
these Treg cells in part because it
promotes the expression of the chemo-
kine receptor CXCR3, which allows accu-
mulation at Th1 cell-inflamed sites (Koch
et al., 2009). Th17 cells require STAT3
transcription factor for their differentia-
tion. Chaudhry et al. (2009) have previ-
ously shown that Treg cells require the
sameSTAT3 in order to selectively control
Th17 cell responses. STAT3 activation in
Treg cells is important for optimal expres-
sion of regulatory molecules including
EBI3, which is probably secreted together
with IL-12p35 chain to form the cytokineIL-35 (Vignali et al., 2008) and IL-10
(Chaudhry et al., 2009). In addition,
STAT3 activation gives these Treg cells
certain characteristics of Th17 cells
including expression of CCR6, IL-1R,
and IL-6R (Figure 1). CCR6 allows
STAT3+ Treg cells to migrate to the in-
flamed tissues in which a Th17 cell
response is taking place. Indeed, some
CCR6 ligands such as CCL20 are
produced by Th17 cells themselves. The
expression of IL-1R and IL-6R may also
participate in suppression of Th17 cells
by competing for pools of IL-1 and IL-6
that are required for Th17 cell
differentiation.
Chaudhry et al. (2011) now show that,
among the different STAT3-activating
cytokines, Treg cells specifically require
IL-10 signaling for activation of STAT3
(Figure 1). Mice in which IL-10R has
been selectively deleted in Treg cell
develop spontaneous colitis. Il10ra/
Treg cells also fail to control colitis when
they are cotransfected with activated
CD4+ T cells into Rag2/mice. Although
other CD4+ and CD8+ T cell subsets
induce STAT3 phosphorylation in
response to both IL-6 and IL-10, Treg
cells selectively respond to IL-10 but not
to IL-6. This insensitivity to IL-6 wasImmunityconfirmed by absence of phenotype in
mice with Treg cell-specific IL-6Ra dele-
tion (although the latter experiment
should be interpreted with caution
because soluble IL-6Ra may complex
with IL-6 and allow signaling through
gp130 on Treg). The ability of STAT3 to
bind to the Il10 gene promoter in ChIP
experiments and the reduced expression
of Il10 in Stat3/ or Il10ra/ Treg cells
suggest that part of the mechanism
involves IL-10 inducing its own expres-
sion in these cells (Chaudhry et al., 2009;
Chaudhry et al., 2011).
Deficiency in STAT3 or IL-10R in Treg
cells interfered with their capacity to
suppress Th17 cell responses but did
not affect regulation of Th1 or Th2 cell
inflammation. These data contrast with
a study in which IL-10 was required for
Treg cell function and Foxp3 expression
(Murai et al., 2009). An important differ-
ence in the Murai et al. (2009) study is
that the IL-10 dependence was reported
only in mice with colitis, whereas
Chaudhry et al. (2011) analyzed Treg cell
number and expression of Foxp3 in the
spleen of intact mice with limited inflam-
mation beside the spontaneous colitis in
older animals.
Huber et al. (2011) focus on the role of
IL-10 signaling on Th17 cells, employing
a transgenic mouse with expression of
a dominant-negative IL-10R on all T cells
(CD4-DNIL-10R). Under normal condi-
tions, these mice have little phenotype,
but inflammatory conditions lead to
expansion of Th17 effector cells and a
resulting increase in inflammation-driven
pathology that is normally controlled by
IL-10. This is consistent with expression
of the IL-10R, which they find at low
amounts on naive T cells but higher on
inflammatory T cells and particularly
Th17 cells. CD3 antibody treatment was
used for driving systemic and intestinal
inflammation and accumulation of Th17
cells. In the absence of T cell IL-10
signaling, mice were unable to control
systemic inflammation, resulting in much
higher systemic cytokine production,
greater weight loss, and extensive fatality.
Becausedefective IL-10 signaling showed
the most profound effects on the Th17
and IFN-g-producing Th17+Th1 cell sub-
sets, Huber et al. (2011) tested the
IL-10R requirement with colitis elicited
by adoptive T cell transfer of primed
Th17 cells into Rag1/ hosts. This Th1734, April 22, 2011 ª2011 Elsevier Inc. 461
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Previewscell-mediated colitis was suppressed by
cotransfer of CD4+FoxP3IL-10+ Tr1 cells
or ofCD4+FoxP3+Tregcells, andcritically,
this suppression required IL-10 signaling
in the Th17 effector cells (Figure 1). Inter-
estingly, administration of IL-10 alone
was able to reduce elevated frequencies
of colonic and mesenteric lymph node
Th17 and Th17+Th1 cells, suggesting
that other suppressive activities of Treg
cells are not required for suppression of
Th17 cells. Furthermore, the requirement
for IL-10 signaling only applied to the
Th17 and Th17+Th1 subsets of T cells
and did not affect Treg cell frequencies,
Tr1 cell frequencies or numbers of
Th1 cells. Therefore, and consistent with
Chaudhry et al. (2011), the direct regula-
tion of inflammatory T cells by IL-10
appears to apply uniquely to the Th17
cell lineage.
A role for IL-10 signaling on Treg cells
as described by Chaudhry et al. (2011) is
not entirely excluded in the models used
by Huber et al. (2011). Notably, the Th17
cells generated from the CD4-DNIL-10R
transgenic mice have developed in the
absence of IL-10R signaling by all
T cells, so the Th17 cell-precursors may
be indirectly affected by absence of
IL-10R on Treg cells. Furthermore, no
Treg cell populations lacking IL-10R
sensitivity were specifically used in their
studies. Therefore, the relative and
context-dependent requirements of
IL-10 signaling on Treg and Th17 cells
and requirements for antigen-presenting
cells in these signaling networks remain
to be fully determined.
The degree of colitis and mortality
reported by Chaudhry et al. (2009) and
Chaudhry et al. (2011) for mice with Treg
cell-specific deletion of Stat3 or Il10ra
was much more severe than that
observed in total IL-10-deficient mice or
in the T cell dominant-negative IL-10R462 Immunity 34, April 22, 2011 ª2011 Elsevmouse (Huber et al., 2011). It is possible
that the pathology in the Treg cell-specific
deletion is due to activating functions of
IL-10 for both innate and adaptive effector
cells that are not counterbalanced by fully
functional Treg cells. Alternatively, differ-
ences in the commensal flora between
animal facilities may explain the different
susceptibilities to colitis, and also the
capacities of distinct cell populations to
produce IL-10 and hence contribute to
regulatory responses (Atarashi et al.,
2011).
The contrasting ability of different
STAT3-activating cytokines to promote
and inhibit Th17 cell functions is intriguing
and remains to be explained. IL-6 (and
IL-23) drives Th17 cell differentiation and
proliferation through a mechanism that
requires STAT3, whereas IL-10 directly
inhibits Th17 cells (Huber et al., 2011).
STAT3 signaling leads to expression
of suppressor of cytokine signaling-3
(SOCS3), which forms negative feedback
inhibition on STAT3 signaling. IL-6 sig-
naling through the gp130 receptor is
sensitive to inhibition by SOCS3, whereas
IL-10 is capable of sustained STAT3 acti-
vation despite its induction of SOCS3
(Lang et al., 2003). Given that SOCS3 in
T cells plays a role in limiting Th17 cell
development (Chen et al., 2006), a likely
mechanism involves the induction of
SOCS3 by IL-10 and its subsequent
suppression of IL-6 (or possibly IL-23)
signaling.
The new studies also elaborate the
concept of Treg cells co-opting the tran-
scriptional program of the effector cells
that they regulate. STAT3 activation is
shared by Th17 cell-selective Treg and
Th17 effector cells, but it is induced
downstream of different cytokines and it
regulates different transcriptional targets,
in particular IL-10 in Treg cells and IL17
and other Th17 cytokines in Th17 cells.ier Inc.Overall, the data from these two papers
(Chaudhry et al., 2011; Huber et al.,
2011) and other recent studies have
changed our appreciation of Treg cells
from one of nonselective anti-inflamma-
tory cells to specificmodulators of distinct
immune responses. The fine-tuned
control conveyed by IL-10 signaling on
T cells during Th17 cell inflammation is
a key link in this regulatory network.
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